Minimal residual disease monitoring in multiple myeloma

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 1, 2002, Pages 197-222

  Davies, Faith E ^a   Rawstron, Andrew C ^a   Owen, Roger G ^a   Morgan, Gareth J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Complete response; Electrophoresis; Flow cytometry; Immunofixation; Multiple myeloma; PCR

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; PARAPROTEIN; PLASMA PROTEIN; STEROID; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PATIENT MONITORING; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVAL; TISSUE FIXATION; AUTOTRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; ELECTROPHORESIS; INTERMETHOD COMPARISON; MONITORING; REVIEW; GENETICS; IMMUNOGLOBULIN GENE; IMMUNOLOGY; IMMUNOPHENOTYPING; METHODOLOGY; PRACTICE GUIDELINE; PROGNOSIS;

FLOW CYTOMETRY; GENES, IMMUNOGLOBULIN; GUIDELINES; HUMANS; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PARAPROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS;

EID: 0036009616     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0192     Document Type: Article

References (61)

1. Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients
2. Infusion of vincristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma
3. High dose intravenous melphalan for plasma-cell leukaemia and myeloma
4. Intensive treatment of multiple myeloma and criteria for complete remission
5. A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
6. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
7. Myeloma Subcommittee of the EBMT. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation
8. Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies
9. Serum free light-chain measurements for identifying and monitoring patients with non-secretory multiple myeloma
10. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an lgH(-) subgroup of multiple myeloma
11. Immunoglobulin gene rearrangement in multiple-myeloma: Limitations of Southern blot analysis
12. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay
13. Comparison of different polymerase chain reaction-based approaches for clonality assessment of immunoglobulin heavy-chain gene rearrangements in B-cell neoplasia
14. Assessment of IgH PCR strategies in multiple myeloma
15. Description of a novel FRI IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies
16. Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers
17. Detection of immunoglobulin heavy chain genes rearrangements in B-cell leukemias, lymphomas, multiple myelomas, monoclonal and polyclonal gammopathies
18. Immunoglobulin lambda isotype gene rearrangements in B cell malignancies
19. Heteroduplex PCR analysis of rearranged immunoglobulin genes for clonality assessment in multiple myeloma
20. Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: A new molecular target for detection of minimal residual disease
21. Comparison of fluorescent consensus IgH PCR and allele-specific oligonucleotide probing in the detection of minimal residual disease in childhood ALL
22. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia
23. Heteroduplex analysis of VDJ amplified segments from rearranged IgH genes for clonality assessments in B-cell non-Hodgkin's lymphoma. A comparison between different strategies
24. + T cells in patients with multiple myeloma and paraproteinemia
25. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma
26. Oligoclonal bands and Ig Isotype switching in multiple myeloma treated with high dose therapy and hematopoietic cell transplantations
27. The impact of attaining a minimal disease state following high dose melphalan and autologous transplantation for multiple myeloma
28. Multiple myeloma related cells in patients undergoing peripheral blood stem cell transplantation
29. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts
30. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma
31. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes
32. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
33. Isolation and characterisation of recombination events involving immunoglobulin heavy chain switch regions in multiple myeloma using long distance vectorette PCR
34. Circulating plasma cells in multiple myeloma: Characterisation and correlation with disease stage
35. B lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B cell progenitors and plasma cell precursors
36. The interleukin 6 receptor alpha chain (CD126) is expressed by neoplastic but not normal plasma cells
37. Flow monitoring in myeloma identifies the relationship between normal and neoplastic plasma cells and predicts disease progression
38. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis
39. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma
40. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of French Registry on autologous transplantation in multiple myeloma
41. Intensive combined therapy for previously untreated aggressive myeloma
42. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population based study
43. Autologous peripheral blood stem cell transplantation for multiple myeloma: A report of 259 cases from the Spanish Registry
44. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
45. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment
46. Total therapy with tandem transplants for newly diagnosed multiple myeloma
47. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma
48. + selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: Tumour cell contamination and outcome
49. High dose sequential chemoradiotherapy in multiple myeloma: Residual tumour cells are detectable in bone marrow and peripheral blood cell harvest and after autografting
50. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
51. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
52. Kinetics of paraprotein clearance after autografting for multiple myeloma
53. T cell responses elicited by immunisation of multiple myeloma patients with idiotypic M protein plus GM-CSF in remission after autologous transplantation
54. Presentation of tumour cell antigens
55. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation
56. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells
57. Minimal peripheral blood cells carrying clonal markers of B cell disorders: Evidence for monoclonality of circulating lymphocytes in patients with multiple myeloma
58. The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation
59. Syngeneic transplantation in multiple myeloma - A case-matched comparison with autologous and allogeneic transplantation
60. + selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
61. Purging of autologous peripheral blood stem cells using cell selection does not improve overall or progression free survival after high dose chemotherapy for multiple myeloma: Results of a multicenter randomised controlled trial